Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) | Starlite/ChEMBL | References |
Homo sapiens | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | Starlite/ChEMBL | References |
Homo sapiens | arachidonate 5-lipoxygenase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma japonicum | ko:K00461 arachidonate 5-lipoxygenase [EC1.13.11.34], putative | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma mansoni | lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma japonicum | IPR001024,Lipoxygenase, LH2;IPR013819,Lipoxygenase, C-terminal,domain-containing | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | dihydrofolate reductase | 0.2765 | 1 | 1 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.2765 | 1 | 0.5 |
Echinococcus multilocularis | dihydrofolate reductase | 0.2765 | 1 | 1 |
Schistosoma mansoni | lipoxygenase | 0.0142 | 0.0161 | 0.0161 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1057 | 0.3593 | 0.5 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.1057 | 0.3593 | 0.5 |
Echinococcus granulosus | dihydrofolate reductase | 0.2765 | 1 | 1 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.2765 | 1 | 0.5 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.1057 | 0.3593 | 0.5 |
Brugia malayi | Dihydrofolate reductase | 0.2765 | 1 | 0.5 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.2765 | 1 | 0.5 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.1057 | 0.3593 | 0.5 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1057 | 0.3593 | 0.5 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.2765 | 1 | 0.5 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.1057 | 0.3593 | 0.5 |
Chlamydia trachomatis | dihydrofolate reductase | 0.2765 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | 0 | Comparative activity of the compound versus Dihydrodimethylbenzofurans in the CPE assay; +, indicates compound is orally active with an ED35 or ED50 = 15 mg/kg or with >/= 25% inhibition of paw swelling at a dose = 50 mg/kg | ChEMBL. | 9719605 |
CPE index (functional) | = 0.77 | Inhibition of paw swelling relative to the tebufelone in rat. Value was reported as Carrageenan paw edema index | ChEMBL. | 9719605 |
IC50 (binding) | = 0.02 uM | Inhibitory activity against prostaglandin G/H synthase 1 (COX-1) | ChEMBL. | 9719605 |
IC50 (binding) | = 0.02 uM | Inhibitory activity against prostaglandin G/H synthase 1 (COX-1) | ChEMBL. | 9719605 |
IC50 (binding) | = 0.035 uM | Inhibitory activity against prostaglandin G/H synthase 2 (COX-2) | ChEMBL. | 9719605 |
IC50 (binding) | = 0.035 uM | Inhibitory activity against prostaglandin G/H synthase 2 (COX-2) | ChEMBL. | 9719605 |
IC50 (binding) | = 6 uM | Inhibition of 5-Lipoxygenase(5-LOX) | ChEMBL. | 9719605 |
IC50 (binding) | = 6 uM | Inhibition of 5-Lipoxygenase(5-LOX) | ChEMBL. | 9719605 |
Inhibition (functional) | = 13 % | Analgesic activity in phenylquinone-induced abdominal constriction assay (PAC) | ChEMBL. | 9719605 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.